SEC Company Response from TALPHERA, INC. (TLPH) (CIK 0001427925) (TLPH) — Jun 13, 2017
TALPHERA, INC. (TLPH) (CIK 0001427925)
Date: June 13, 2017 · CIK: 0001427925 · Accession: 0001437749-17-011206
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218506
Letter
acrx20170613_corresp.htm
June 13, 2017
Via EDGAR
United States Securities and Exchange Commission
Division of Corporate Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Johnny Gharib
RE:
AcelRx Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed June 5, 2017
File Number: 333-218506
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Filing”) to become effective at 4:00 p.m. Eastern Time on Wednesday, June 14, 2017, or as soon thereafter as is practicable.
Very truly yours,
AcelRx Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm acrx20170613_corresp.htm June 13, 2017 Via EDGAR United States Securities and Exchange Commission Division of Corporate Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Johnny Gharib RE: AcelRx Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed June 5, 2017 File Number: 333-218506 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Filing”) to become effective at 4:00 p.m. Eastern Time on Wednesday, June 14, 2017, or as soon thereafter as is practicable. Very truly yours, AcelRx Pharmaceuticals, Inc. /s/ Jane Wright-Mitchell By: Jane Wright-Mitchell Chief Legal Officer cc: Mark B. Weeks Robert W. Phillips Cooley llp